Showing 1381-1390 of 1644 results for "".
- Ocrelizumab Treatment Associated with Significant Decreases in Blood Levels of Neurofilament Lighthttps://practicalneurology.com/news/ocrelizumab-treatment-associated-with-significant-decreases-in-blood-levels-of-neurofilament-light/2469017/Biomarker data from the ORATORIO and OPERA I clinical trials (NCT01194570 and NCT01247324) of ocrelizumab (Ocrevus; Genentech, South San Francisco, CA) for relapsing and pri
- Combination Drug Shows Promise for Treating Alzheimer's-Associated Agitationhttps://practicalneurology.com/news/combination-drug-shows-promise-for-treating-alzheimers-associated-agitation/2468788/A combination of deudextromethorphan hydrobromide and quinidine sulfate (AVP-786; Avanir Pharmaceuticals, Alisa Viejo, CA) is being studied as potential treatment of moderate-to-severe agitation in patients with Alzheimer's dementia (AD) (
- The AAIC Presents Lifetime Achievement Awards in Alzheimer Disease Researchhttps://practicalneurology.com/news/the-aaic-presents-lifetime-achievement-awards-in-alzheimers-disease-research/2470542/Three awardees were recognized at the 2024 meeting of the Alzheimer’s Association International Conference (AAIC), receiving AAIC Lifetime Achievement Awards in Alzheimer disease (AD) research. These awards celebrate the leadership, research, and mentorship contributions of senior
- Phenogroups of Migraine Identified With Artificial Intelligence-Guided Topologic Mappinghttps://practicalneurology.com/news/phenogroups-of-migraine-identified-with-artificial-intelligence-guided-topologic-mapping/2469941/Migraine is increasingly as a as a heterogeneous disorder, with a wide variety of headache characteristics, associated symptoms, and treatment responses. In a study presented at the American Headache Society meeting in Denver, CO June 9-12, 2022, Chia-Chun Chiang, MD, senior assoc
- Associations Between NfL Concentrations and Cognitive and Radiologic Outcomes Revealed in Study of Individuals with RMS Treated with Zeposiahttps://practicalneurology.com/news/associations-between-relapsing-ms-treatment-with-zeposia-nfl-concentrations-and-cognitive-and-radiologic-outcomes-revealed-in-1-year-interim-analysis-data/2473801/Research presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2025 demonstrated that neurofilament light chain (NfL) may be a useful biomarker for both cognitive and radiologic outcomes in early relapsing multiple sclerosis (RMS). The findings resul
- Using a Salt Substitute Associated with Significant Reduction in Stroke and Death in Those with a History of Strokehttps://practicalneurology.com/news/using-a-salt-substitute-associated-with-significant-reduction-in-stroke-and-death-in-those-with-a-history-of-stroke/2473787/Replacing salt with a salt substitute in home cooking may significantly reduce risk of recurrence and all-cause mortality for people who have a history of stroke, according to data published in JAMA Neurology. Findings from a prespecified, secondary subgroup analysis of the China Salt Substitute
- 5 Year Data Show Zeposia Treatment Was Associated with Reduced Brain Volume Loss In Patients with RMShttps://practicalneurology.com/news/5-year-data-reveal-zeposia-treatment-was-associated-with-reduced-brain-volume-loss-in-patients-with-rms/2470586/Results from the phase 3 DAYBREAK open-label extension trial for Zeposia (ozanimod; Bristol Myers Squibb, New York, NY) showed sustained reductions in brain volume loss and consistent safety profiles for up to 5 years of continuous treatment in individuals with relapsing forms of multiple scleros
- Investigational Nuclear Receptor Therapy Associated with Favorable Outcomes as Potential Alzheimer Disease Treatmenthttps://practicalneurology.com/news/investigational-nuclear-receptor-therapy-associated-with-favorable-outcomes-as-potential-alzheimer-disease-treatment/2470549/Treatment with T3D-959 (T3D Therapeutics, Research Triangle Park, NC), an oral small molecule brain-penetrating PPARδ/γ dual nuclear receptor agonist, was shown to slow cognitive decline and reduce amyloid plaque burden in people with mild-to-moderate Alzheimer disease (AD). T3D-959 t
- Kesimpta Associated with Reductions in Multiple Sclerosis Disease Activity Across Race and Ethnic Groupshttps://practicalneurology.com/news/kesimpta-associated-with-reductions-in-multiple-sclerosis-disease-activity-across-race-and-ethnic-groups/2470529/Kesimpta (ofatumumab; Novartis, Cambridge, MA) was shown to be more effective than Aubagio (teriflunomide; Genzyme, Cambridge, MA) in reducing disease activity across ethnic and racial groups in people with relapsing-remitting multiple sclerosis (RRMS). Results of a post-hoc analysis of 2 previou
- PrimeC Treatment for ALS Associated With Functional Improvements and Extended Survival According to 12-Month PARADIGM Datahttps://practicalneurology.com/news/primec-treatment-for-als-associated-with-functional-improvements-and-extended-survival-according-to-12-month-paradigm-data/2470524/New 12-month results from the PARADIGM clinical trial (NCT05357950) demonstrated a significant improvement in the rate of decline of Amyotrophic Lateral Sclerosis (ALS) Functional Rating Scale-Revised (ALSFRS-R) scores and survival rates for adults with ALS treated with PrimeC (ciprofloxacin/cele